Search

Your search keyword '"Pugliese, N."' showing total 464 results
Start Over Author "Pugliese, N."
464 results on '"Pugliese, N."'

1. Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study

Author

Picardi, M., Vincenzi, A., Giordano, C., Fazio, L. De, Pugliese, N., Scarpa, A., Vigliar, E., Troncone, G., Russo, D., Mascolo, M., Esposito, G., Prastaro, M., Santoro, C., Esposito, R., Tocchetti, C. G., Mainolfi, C., Fonti, R., Vecchio, S. Del, Carchia, M., and Quagliano, C.

Abstract

In elderly patients with high‐risk classic Hodgkin lymphoma (c‐HL), we evaluated the impact of a new modality treatment without bleomycin, that is, liposomal doxorubicin (NPLD)‐based regimen plus consolidation radiotherapy of residual nodal masses (RNMs), on overall survival (OS) and progression free survival (PFS). In this retrospective study (2013–2023) conducted in tertiary hospitals in the bay of Naples (Italy), 50 older adults (median age, 69 years; range, 60–89) with advanced stage c‐HL received frontline treatment with MVD ± irradiation. MVD consisted of 25 mg/m2 of NPLD along with standard Vinblastine and Dacarbazine for a total of 6 cycles (twelve iv administrations, every 2 weeks) followed by radiation of RNMs with size ≥ 2.5 cm at computed tomography. Patients underwent MVD with a median dose intensity of 92%. At 2‐deoxy‐2[F‐18] fluoro‐D‐glucose positron emission tomography (FDG‐PET), 90% of patients (45/50 patients; one failed to perform final FDG‐PET due to early death) reached complete responses. Altogether, 17 patients (34%) received consolidation radiotherapy of RNMs with Deauville score ≥ 3. At 5‐year median follow‐up, the OS and PFS of the entire population were 87.5% (95% confidence interval [CI], 78.7–97.4) and 81.6% (95% CI, 71.4–93.2), respectively. Eleven patients (22%) experienced grade ≥ 3 adverse events, and 4 of them required hospitalization. Our data suggest that in older adults with high‐risk c‐HL NPLD‐driven strategy (without bleomycin) plus consolidation radiotherapy (if needed) may be a promising up‐front option, to test in phase II clinical trials for improving survival incidence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. OC.16.6: APPLICATION OF MACHINE LEARNING MODEL-3P TO PREDICT PORTAL HYPERTENSION IN PATIENT WITH HEPATOCELLULAR CARCINOMA

Author

Soleri, M., primary, Berardi, F., additional, Bertazzoni, A., additional, Fortunato, M., additional, Ceriani, R., additional, Colapietro, F., additional, Pugliese, N., additional, Masetti, C., additional, Torzilli, G., additional, Pedicini, V., additional, Poretti, D., additional, Rimassa, L., additional, Comito, T., additional, De Nalda, A. Lleo, additional, Aghemo, A.M.G., additional, and De Nicola, S., additional

Published
2024
Full Text
View/download PDF

5. OC.05.2: FIRST AND FURTHER LIVER DECOMPENSATION IN PATIENTS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: WHAT CLINICAL IMPACT?

Author

Pennisi, G., primary, Viganò, M., additional, Fracanzani, A.L., additional, Miele, L., additional, Bugianesi, E., additional, D'Ambrosio, R., additional, Ravaioli, F., additional, Schepis, F., additional, Marra, F., additional, Aghemo, A.M.G., additional, Svegliati Baroni, G., additional, Masarone, M., additional, Valenti, L., additional, Armandi, A., additional, Ciccioli, C., additional, Cerini, F., additional, Colecchia, A., additional, Gasbarrini, A., additional, Infantino, G., additional, Liguori, A., additional, Pelusi, S., additional, Saltini, D., additional, Lampertico, P., additional, Persico, M., additional, Pugliese, N., additional, Tulone, A., additional, Di Marco, V., additional, Cammà, C., additional, and Petta, S., additional

Published
2024
Full Text
View/download PDF

7. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma

Author

Picardi, M., Fonti, R., Della Pepa, R., Giordano, C., Pugliese, N., Nicolai, E., Salvatore, M., Mainolfi, C., Venetucci, P., Rascato, M.G., Cappuccio, I., Mascolo, M., Vigliar, E., Troncone, G., Del Vecchio, S., and Pane, F.

Published
2020
Full Text
View/download PDF

8. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer

Author

Vigano, M, La Milia, M, Grassini, M, Pugliese, N, De Giorgio, M, Fagiuoli, S, Vigano M., La Milia M., Grassini M. V., Pugliese N., De Giorgio M., Fagiuoli S., Vigano, M, La Milia, M, Grassini, M, Pugliese, N, De Giorgio, M, Fagiuoli, S, Vigano M., La Milia M., Grassini M. V., Pugliese N., De Giorgio M., and Fagiuoli S.

Abstract

Small molecule protein kinase inhibitors (PKIs) have become an effective strategy for cancer patients. However, hepatotoxicity is a major safety concern of these drugs, since the majority are reported to increase transaminases, and few of them (Idelalisib, Lapatinib, Pazopanib, Pexidartinib, Ponatinib, Regorafenib, Sunitinib) have a boxed label warning. The exact rate of PKI-induced hepatoxicity is not well defined due to the fact that the majority of data arise from pre-registration or registration trials on fairly selected patients, and the post-marketing data are often based only on the most severe described cases, whereas most real practice studies do not include drug-related hepatotoxicity as an end point. Although these side effects are usually reversible by dose adjustment or therapy suspension, or by switching to an alternative PKI, and fatality is uncommon, all patients undergoing PKIs should be carefully pre-evaluated and monitored. The management of this complication requires an individually tailored reappraisal of the risk/benefit ratio, especially in patients who are responding to therapy. This review reports the currently available data on the risk and management of hepatotoxicity of all the approved PKIs.

Published
2023

9. Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia

Author

Inzoli, E, Crisa, E, Pugliese, N, Civettini, I, Lanzarone, G, Castelli, A, Martinelli, V, Montelisciani, L, Antolini, L, Gambacorti-Passerini, C, Elli, E, Inzoli E., Crisa E., Pugliese N., Civettini I., Lanzarone G., Castelli A., Martinelli V., Montelisciani L., Antolini L., Gambacorti-Passerini C., Elli E. M., Inzoli, E, Crisa, E, Pugliese, N, Civettini, I, Lanzarone, G, Castelli, A, Martinelli, V, Montelisciani, L, Antolini, L, Gambacorti-Passerini, C, Elli, E, Inzoli E., Crisa E., Pugliese N., Civettini I., Lanzarone G., Castelli A., Martinelli V., Montelisciani L., Antolini L., Gambacorti-Passerini C., and Elli E. M.

Abstract

Objectives: Erythropoiesis-stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B-ESA), in myelofibrosis (MF) is not well established.Methods: This study retrospectively collected data on 96 MF patients treated with B-ESA (alpha/zeta) for the management of anemia to assess safety, efficacy (anemia response [AR]), and survival.Results: Seventy-seven patients (80%) obtained AR. The median time to AR was 2.5 months. In multivariate analysis, significant predictive factors of AR were transfusion independency (p = .006) and ferritin levels < 200 ng/ml (p = .009) at baseline. After a median follow-up of 43.8 months from diagnosis, 38 patients (39%) died, 11 (28.9%) from leukemic evolution. Only two patients (2.5%) stopped B-ESA for toxicity. The 24-month survival was significantly affected by response to B-ESA (70.8% in AR vs. 55.3% in non-responder patients, p = .016). In multivariate analysis, age & LE; 70 years (p = .029) and Hb > 8.5 g/dl (p = .047) at baseline were significantly associated with improved survival, with a trend for longer survival in AR patients (p = .06).Conclusions: B-ESA seems to be an effective and well-tolerated option for anemia treatment in the MF setting. This strategy deserves further clinical investigation.

Published
2023

11. Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma

Author

Picardi, M., primary, Giordano, C., additional, Pugliese, N., additional, Mascolo, M., additional, Varricchio, S., additional, Troncone, G., additional, Vigliar, E., additional, Bellavicine, C., additional, Lamagna, M., additional, Lisi, D., additional, Vincenzi, A., additional, and Pane, F., additional

Published
2023
Full Text
View/download PDF

15. Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma.

Author

Picardi, M., Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A., and Pane, F.

Subjects
DIFFUSE large B-cell lymphomas, DOXORUBICIN, SPECKLE tracking echocardiography
Abstract

This article explores the use of a new treatment regimen, R-COMP-DIx6, in the treatment of primary mediastinal large B-cell lymphoma (PMBL) and mediastinal gray zone lymphoma (MGZL). The study found that the regimen, which includes an increased dose of liposomal-encapsulated doxorubicin (Myocet™), resulted in a high rate of complete metabolic response and favorable progression-free survival rate in patients. The study also examined the impact of tumor-infiltrating macrophages on treatment outcomes. However, the study had a small sample size and further research is needed to determine the effectiveness of this treatment in a larger clinical trial. [Extracted from the article]

Published
2024
Full Text
View/download PDF

16. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study

Author

Elli, E, Di Veroli, A, Bartoletti, D, Iurlo, A, Carmosino, I, Benevolo, G, Abruzzese, E, Bonifacio, M, Bergamaschi, M, Polverelli, N, Caramella, M, Cilloni, D, Tiribelli, M, Pugliese, N, Caocci, G, Crisa, E, Porrini, R, Markovic, U, Renso, R, Auteri, G, Cattaneo, D, Trawinska, M, Scaffidi, L, Biale, L, Bucelli, C, Breccia, M, Gambacorti Passerini, C, Palumbo, G, Latagliata, R, Palandri, F, Elli E. M., Di Veroli A., Bartoletti D., Iurlo A., Carmosino I., Benevolo G., Abruzzese E., Bonifacio M., Bergamaschi M., Polverelli N., Caramella M., Cilloni D., Tiribelli M., Pugliese N., Caocci G., Crisa E., Porrini R., Markovic U., Renso R., Auteri G., Cattaneo D., Trawinska M. M., Scaffidi L., Biale L., Bucelli C., Breccia M., Gambacorti Passerini C., Palumbo G. A., Latagliata R., Palandri F., Elli, E, Di Veroli, A, Bartoletti, D, Iurlo, A, Carmosino, I, Benevolo, G, Abruzzese, E, Bonifacio, M, Bergamaschi, M, Polverelli, N, Caramella, M, Cilloni, D, Tiribelli, M, Pugliese, N, Caocci, G, Crisa, E, Porrini, R, Markovic, U, Renso, R, Auteri, G, Cattaneo, D, Trawinska, M, Scaffidi, L, Biale, L, Bucelli, C, Breccia, M, Gambacorti Passerini, C, Palumbo, G, Latagliata, R, Palandri, F, Elli E. M., Di Veroli A., Bartoletti D., Iurlo A., Carmosino I., Benevolo G., Abruzzese E., Bonifacio M., Bergamaschi M., Polverelli N., Caramella M., Cilloni D., Tiribelli M., Pugliese N., Caocci G., Crisa E., Porrini R., Markovic U., Renso R., Auteri G., Cattaneo D., Trawinska M. M., Scaffidi L., Biale L., Bucelli C., Breccia M., Gambacorti Passerini C., Palumbo G. A., Latagliata R., and Palandri F.

Abstract

Deferasirox (DFX) is used for the management of iron overload (IOL) in many haematological malignancies including myelofibrosis (MF). The ‘RUX-IOL’ study retrospectively collected 69 MF patients treated with ruxolitinib (RUX) and DFX for IOL to assess: safety, efficacy in term of iron chelation response (ICR) and erythroid response (ER), and impact on overall survival of the combination therapy. The RUX–DFX therapy was administered for a median time of 12.4 months (interquartile range 3.1–71.2). During treatment, 36 (52.2%) and 34 (49.3%) patients required RUX and DFX dose reductions, while eight (11.6%) and nine (13.1%) patients discontinued due to RUX- or DFX-related adverse events; no unexpected toxicity was reported. ICR and ER were achieved by 33 (47.8%) and 32 patients (46.4%) respectively. Thirteen (18.9%) patients became transfusion-independent. Median time to ICR and ER was 6.2 and 2 months respectively. Patients achieving an ER were more likely to obtain an ICR also (p = 0.04). In multivariable analysis, the absence of leukocytosis at baseline (p = 0.02) and achievement of an ICR at any time (p = 0.02) predicted improved survival. In many MF patients, the RUX–DFX combination provided ICR and ER responses that correlated with improved outcome in the absence of unexpected toxicities. This strategy deserves further clinical investigation.

Published
2022

17. Liposomal doxorubicin supercharge‐containing frontline treatment for diffuse large B‐cell lymphoma or classical Hodgkin lymphoma: preliminary results of a phase II study

Author

Giordano, C., primary, Picardi, M., additional, Pugliese, N., additional, Della Pepa, R., additional, D'Ambrosio, A., additional, Muriano, F., additional, Rascato, M. G., additional, Esposito, M., additional, Fatigati, C., additional, Esposito, R., additional, Russo, D., additional, Vigliar, E., additional, Tocchetti, C., additional, Fonti, R., additional, Prastaro, M., additional, Del Vecchio, S., additional, Esposito, G., additional, Mainolfi, C., additional, Mascolo, M., additional, Troncone, G., additional, and Pane, F., additional

Published
2023
Full Text
View/download PDF

18. Multi-organ sonographic assessment of congestion has incremental prognostic value in outpatients with heart failure irrespective of left ventricular ejection fraction

Author

Pugliese, N R, primary, Pellicori, P, additional, Filidei, F, additional, Del Punta, L, additional, De Biase, N, additional, Balletti, A, additional, Di Fiore, V, additional, Mengozzi, A, additional, Taddei, S, additional, Gargani, L, additional, Mullens, W, additional, Cleland, J G F, additional, and Masi, S, additional

Published
2023
Full Text
View/download PDF

21. The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation

Author

Maloberti, A, Mengozzi, A, Russo, E, Cicero, A, Angeli, F, Agabiti Rosei, E, Barbagallo, C, Bernardino, B, Bombelli, M, Cappelli, F, Casiglia, E, Cianci, R, Ciccarelli, M, Cirillo, M, Cirillo, P, Desideri, G, D'Elia, L, Dell'Oro, R, Facchetti, R, Ferri, C, Galletti, F, Giannattasio, C, Gesualdo, L, Iaccarino, G, Lippa, L, Mallamaci, F, Masi, S, Masulli, M, Mazza, A, Muiesan, M, Nazzaro, P, Parati, G, Palatini, P, Pauletto, P, Pontremoli, R, Pugliese, N, Quarti-Trevano, F, Rattazzi, M, Reboldi, G, Rivasi, G, Salvetti, M, Tikhonoff, V, Tocci, G, Ungar, A, Verdecchia, P, Viazzi, F, Volpe, M, Virdis, A, Grassi, G, Borghi, C, Maloberti, Alessandro, Mengozzi, Alessandro, Russo, Elisa, Cicero, Arrigo Francesco Giuseppe, Angeli, Fabio, Agabiti Rosei, Enrico, Barbagallo, Carlo Maria, Bernardino, Bruno, Bombelli, Michele, Cappelli, Federica, Casiglia, Edoardo, Cianci, Rosario, Ciccarelli, Michele, Cirillo, Massimo, Cirillo, Pietro, Desideri, Giovambattista, D'Elia, Lanfranco, Dell'Oro, Raffaella, Facchetti, Rita, Ferri, Claudio, Galletti, Ferruccio, Giannattasio, Cristina, Gesualdo, Loreto, Iaccarino, Guido, Lippa, Luciano, Mallamaci, Francesca, Masi, Stefano, Masulli, Maria, Mazza, Alberto, Muiesan, Maria Lorenza, Nazzaro, Pietro, Parati, Gianfranco, Palatini, Paolo, Pauletto, Paolo, Pontremoli, Roberto, Pugliese, Nicola Riccardo, Quarti-Trevano, Fosca, Rattazzi, Marcello, Reboldi, Gianpaolo, Rivasi, Giulia, Salvetti, Massimo, Tikhonoff, Valerie, Tocci, Giuliano, Ungar, Andrea, Verdecchia, Paolo, Viazzi, Francesca, Volpe, Massimo, Virdis, Agostino, Grassi, Guido, Borghi, Claudio, Maloberti, A, Mengozzi, A, Russo, E, Cicero, A, Angeli, F, Agabiti Rosei, E, Barbagallo, C, Bernardino, B, Bombelli, M, Cappelli, F, Casiglia, E, Cianci, R, Ciccarelli, M, Cirillo, M, Cirillo, P, Desideri, G, D'Elia, L, Dell'Oro, R, Facchetti, R, Ferri, C, Galletti, F, Giannattasio, C, Gesualdo, L, Iaccarino, G, Lippa, L, Mallamaci, F, Masi, S, Masulli, M, Mazza, A, Muiesan, M, Nazzaro, P, Parati, G, Palatini, P, Pauletto, P, Pontremoli, R, Pugliese, N, Quarti-Trevano, F, Rattazzi, M, Reboldi, G, Rivasi, G, Salvetti, M, Tikhonoff, V, Tocci, G, Ungar, A, Verdecchia, P, Viazzi, F, Volpe, M, Virdis, A, Grassi, G, Borghi, C, Maloberti, Alessandro, Mengozzi, Alessandro, Russo, Elisa, Cicero, Arrigo Francesco Giuseppe, Angeli, Fabio, Agabiti Rosei, Enrico, Barbagallo, Carlo Maria, Bernardino, Bruno, Bombelli, Michele, Cappelli, Federica, Casiglia, Edoardo, Cianci, Rosario, Ciccarelli, Michele, Cirillo, Massimo, Cirillo, Pietro, Desideri, Giovambattista, D'Elia, Lanfranco, Dell'Oro, Raffaella, Facchetti, Rita, Ferri, Claudio, Galletti, Ferruccio, Giannattasio, Cristina, Gesualdo, Loreto, Iaccarino, Guido, Lippa, Luciano, Mallamaci, Francesca, Masi, Stefano, Masulli, Maria, Mazza, Alberto, Muiesan, Maria Lorenza, Nazzaro, Pietro, Parati, Gianfranco, Palatini, Paolo, Pauletto, Paolo, Pontremoli, Roberto, Pugliese, Nicola Riccardo, Quarti-Trevano, Fosca, Rattazzi, Marcello, Reboldi, Gianpaolo, Rivasi, Giulia, Salvetti, Massimo, Tikhonoff, Valerie, Tocci, Giuliano, Ungar, Andrea, Verdecchia, Paolo, Viazzi, Francesca, Volpe, Massimo, Virdis, Agostino, Grassi, Guido, and Borghi, Claudio

Abstract

The relationship between Serum Uric Acid (UA) and Cardiovascular (CV) diseases has already been extensively evaluated, and it was found to be an independent predictor of all-cause and cardiovascular mortality but also acute coronary syndrome, stroke and heart failure. Similarly, also many papers have been published on the association between UA and kidney function, while less is known on the role of UA in metabolic derangement and, particularly, in metabolic syndrome. Despite the substantial number of publications on the topic, there are still some elements of doubt: (1) the better cut-off to be used to refine CV risk (also called CV cut-off); (2) the needing for a correction of UA values for kidney function; and (3) the better definition of its role in metabolic syndrome: is UA simply a marker, a bystander or a key pathological element of metabolic dysregulation?. The Uric acid Right for heArt Health (URRAH) project was designed by the Working Group on uric acid and CV risk of the Italian Society of Hypertension to answer the first question. After the first papers that individuates specific cut-off for different CV disease, subsequent articles have been published responding to the other relevant questions. This review will summarise most of the results obtained so far from the URRAH research project.

Published
2023

22. Serum Uric Acid Predicts All-Cause and Cardiovascular Mortality Independently of Hypertriglyceridemia in Cardiometabolic Patients without Established CV Disease: A Sub-Analysis of the URic acid Right for heArt Health (URRAH) Study

Author

Mengozzi, A, Pugliese, N, Desideri, G, Masi, S, Angeli, F, Barbagallo, C, Bombelli, M, Cappelli, F, Casiglia, E, Cianci, R, Ciccarelli, M, Cicero, A, Cirillo, M, Cirillo, P, Dell’Oro, R, D’Elia, L, Ferri, C, Galletti, F, Gesualdo, L, Giannattasio, C, Grassi, G, Iaccarino, G, Lippa, L, Mallamaci, F, Maloberti, A, Masulli, M, Mazza, A, Muiesan, M, Nazzaro, P, Palatini, P, Parati, G, Pontremoli, R, Quarti-Trevano, F, Rattazzi, M, Reboldi, G, Rivasi, G, Russo, E, Salvetti, M, Tikhonoff, V, Tocci, G, Ungar, A, Verdecchia, P, Viazzi, F, Volpe, M, Borghi, C, Virdis, A, Mengozzi, Alessandro, Pugliese, Nicola Riccardo, Desideri, Giovambattista, Masi, Stefano, Angeli, Fabio, Barbagallo, Carlo Maria, Bombelli, Michele, Cappelli, Federica, Casiglia, Edoardo, Cianci, Rosario, Ciccarelli, Michele, Cicero, Arrigo F. G., Cirillo, Massimo, Cirillo, Pietro, Dell’Oro, Raffaella, D’Elia, Lanfranco, Ferri, Claudio, Galletti, Ferruccio, Gesualdo, Loreto, Giannattasio, Cristina, Grassi, Guido, Iaccarino, Guido, Lippa, Luciano, Mallamaci, Francesca, Maloberti, Alessandro, Masulli, Maria, Mazza, Alberto, Muiesan, Maria Lorenza, Nazzaro, Pietro, Palatini, Paolo, Parati, Gianfranco, Pontremoli, Roberto, Quarti-Trevano, Fosca, Rattazzi, Marcello, Reboldi, Gianpaolo, Rivasi, Giulia, Russo, Elisa, Salvetti, Massimo, Tikhonoff, Valerie, Tocci, Giuliano, Ungar, Andrea, Verdecchia, Paolo, Viazzi, Francesca, Volpe, Massimo, Borghi, Claudio, Virdis, Agostino, Mengozzi, A, Pugliese, N, Desideri, G, Masi, S, Angeli, F, Barbagallo, C, Bombelli, M, Cappelli, F, Casiglia, E, Cianci, R, Ciccarelli, M, Cicero, A, Cirillo, M, Cirillo, P, Dell’Oro, R, D’Elia, L, Ferri, C, Galletti, F, Gesualdo, L, Giannattasio, C, Grassi, G, Iaccarino, G, Lippa, L, Mallamaci, F, Maloberti, A, Masulli, M, Mazza, A, Muiesan, M, Nazzaro, P, Palatini, P, Parati, G, Pontremoli, R, Quarti-Trevano, F, Rattazzi, M, Reboldi, G, Rivasi, G, Russo, E, Salvetti, M, Tikhonoff, V, Tocci, G, Ungar, A, Verdecchia, P, Viazzi, F, Volpe, M, Borghi, C, Virdis, A, Mengozzi, Alessandro, Pugliese, Nicola Riccardo, Desideri, Giovambattista, Masi, Stefano, Angeli, Fabio, Barbagallo, Carlo Maria, Bombelli, Michele, Cappelli, Federica, Casiglia, Edoardo, Cianci, Rosario, Ciccarelli, Michele, Cicero, Arrigo F. G., Cirillo, Massimo, Cirillo, Pietro, Dell’Oro, Raffaella, D’Elia, Lanfranco, Ferri, Claudio, Galletti, Ferruccio, Gesualdo, Loreto, Giannattasio, Cristina, Grassi, Guido, Iaccarino, Guido, Lippa, Luciano, Mallamaci, Francesca, Maloberti, Alessandro, Masulli, Maria, Mazza, Alberto, Muiesan, Maria Lorenza, Nazzaro, Pietro, Palatini, Paolo, Parati, Gianfranco, Pontremoli, Roberto, Quarti-Trevano, Fosca, Rattazzi, Marcello, Reboldi, Gianpaolo, Rivasi, Giulia, Russo, Elisa, Salvetti, Massimo, Tikhonoff, Valerie, Tocci, Giuliano, Ungar, Andrea, Verdecchia, Paolo, Viazzi, Francesca, Volpe, Massimo, Borghi, Claudio, and Virdis, Agostino

Abstract

High serum uric acid (SUA) and triglyceride (TG) levels might promote high-cardiovascular risk phenotypes across the cardiometabolic spectrum. However, SUA predictive power in the presence of normal and high TG levels has never been investigated. We included 8124 patients from the URic acid Right for heArt Health (URRAH) study cohort who were followed for over 20 years and had no established cardiovascular disease or uncontrolled metabolic disease. All-cause mortality (ACM) and cardiovascular mortality (CVM) were explored by the Kaplan–Meier estimator and Cox multivariable regression, adopting recently defined SUA cut-offs for ACM (≥4.7 mg/dL) and CVM (≥5.6 mg/dL). Exploratory analysis across cardiometabolic subgroups and a sensitivity analysis using SUA/serum creatinine were performed as validation. SUA predicted ACM (HR 1.25 [1.12–1.40], p < 0.001) and CVM (1.31 [1.11–1.74], p < 0.001) in the whole study population, and according to TG strata: ACM in normotriglyceridemia (HR 1.26 [1.12–1.43], p < 0.001) and hypertriglyceridemia (1.31 [1.02–1.68], p = 0.033), and CVM in normotriglyceridemia (HR 1.46 [1.23–1.73], p < 0.001) and hypertriglyceridemia (HR 1.31 [0.99–1.64], p = 0.060). Exploratory and sensitivity analyses confirmed our findings, suggesting a substantial role of SUA in normotriglyceridemia and hypertriglyceridemia. In conclusion, we report that SUA can predict ACM and CVM in cardiometabolic patients without established cardiovascular disease, independent of TG levels.

Published
2023

23. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals

Author

Pelusi, S, Bianco, C, Colombo, M, Cologni, G, Del Poggio, P, Pugliese, N, Prati, D, Pigozzi, M, D'Ambrosio, R, Lampertico, P, Fagiuoli, S, Valenti, L, Pelusi, Serena, Bianco, Cristiana, Colombo, Massimo, Cologni, Giuliana, Del Poggio, Paolo, Pugliese, Nicola, Prati, Daniele, Pigozzi, Marie Graciella, D'Ambrosio, Roberta, Lampertico, Pietro, Fagiuoli, Stefano, Valenti, Luca, Pelusi, S, Bianco, C, Colombo, M, Cologni, G, Del Poggio, P, Pugliese, N, Prati, D, Pigozzi, M, D'Ambrosio, R, Lampertico, P, Fagiuoli, S, Valenti, L, Pelusi, Serena, Bianco, Cristiana, Colombo, Massimo, Cologni, Giuliana, Del Poggio, Paolo, Pugliese, Nicola, Prati, Daniele, Pigozzi, Marie Graciella, D'Ambrosio, Roberta, Lampertico, Pietro, Fagiuoli, Stefano, and Valenti, Luca

Abstract

Background and Aims: Metabolic dysfunction (MD)-associated fatty liver disease has been proposed to identify individuals at risk of liver events irrespectively of the contemporary presence of other liver diseases. The aim of this study was to examine the impact of MD in patients cured of chronic hepatis C (CHC). Patients and Methods: We analysed data from a real-life cohort of 2611 Italian patients cured of CHC with direct antiviral agents and advanced liver fibrosis, without HBV/HIV, transplantation and negative for hepatocellular carcinoma (HCC) history (age 61.4 ± 11.8 years, 63.9% males, median follow-up 34, 24–40 months). Information about ultrasonographic steatosis (US) after sustained virological response was available in 1978. Results: MD affected 58% of patients, diagnosed due to the presence of diabetes (MD-diabetes, 19%), overweight without diabetes (MD-overweight, 37%) or multiple metabolic abnormalities without overweight and diabetes (MD-metabolic, 2%). MD was more frequent than and not coincident with US (32% MD-only, 23% MD-US and 13% US-only). MD was associated with higher liver stiffness (p < 0.05), particularly in patients with MD-diabetes and MD-only subgroups, comprising older individuals with more advanced metabolic and liver disease (p < 0.05). At Cox proportional hazard multivariable analysis, MD was associated with increased risk of HCC (HR 1.97, 95% CI 1.27–3.04; p = 0.0023). Further classification according to diagnostic criteria improved risk stratification (p < 0.0001), with the highest risk observed in patients with MD-diabetes. Patients with MD-only appeared at highest risk since the sustained virological response achievement (p = 0.008), with a later catch-up of those with combined MD-US, whereas US-only was not associated with HCC. Conclusions: MD is more prevalent than US in patients cured of CHC with advanced fibrosis and identifies more accurately individuals at risk of developing HCC.

Published
2023

24. Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic Hepatitis C aged 75 years or older: A multicenter study

Author

Pugliese, N., primary, Calvaruso, V., additional, Masarone, M., additional, D'Ambrosio, R., additional, Battistella, S., additional, Licata, A., additional, Persico, M., additional, Anolli, M.P., additional, Distefano, M., additional, Petta, S., additional, Russo, F.P., additional, Di Marco, V., additional, and Aghemo, A., additional

Published
2023
Full Text
View/download PDF

25. Survey on hepatic sarcoidosis in Italy

Author

Corte, C. Della, primary, Reati, R., additional, Malinverno, F., additional, Arena, I., additional, Campigotto, M., additional, Cardinale, V., additional, Cespiati, A., additional, Degasperi, E., additional, Del Poggio, P., additional, Durante, E., additional, Federico, A., additional, Galati, G., additional, Germani, G., additional, Giannini, G., additional, Marin, R., additional, Martini, A., additional, Mazzarelli, C., additional, Mirici, F., additional, Missale, G., additional, Morana, E., additional, Morelli, M., additional, Pasulo, L., additional, Piras, M., additional, Perricone, G., additional, Pugliese, N., additional, Rapetti, R., additional, Rendina, M., additional, Sciarrone, S., additional, Simone, L., additional, Surace, L., additional, Strona, S., additional, Svegliati B, G., additional, Viganò, M., additional, Manes, G., additional, and Carbone, M., additional

Published
2023
Full Text
View/download PDF

27. High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction

Author

De Nicola, S., primary, Cento, V., additional, Fortunato, M., additional, Masetti, C., additional, Colapietro, F., additional, Pugliese, N., additional, Ceriani, R., additional, Bianchi, I., additional, Pedicini, V., additional, Lanza, E., additional, Torzilli, G., additional, Lleo, A., additional, and Aghemo, A., additional

Published
2023
Full Text
View/download PDF

28. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease

Author

Pennisi, G., primary, Enea, M., additional, Viganò, M., additional, Schepis, F., additional, de Ledinghen, V., additional, Berzigotti, A., additional, Wong, V., additional, Fracanzani, A.L., additional, Sebastiani, G., additional, Romero-Gomez, M., additional, Bugianesi, E., additional, Svegliati-Baroni, G., additional, Marra, F., additional, Aghemo, A., additional, Valenti, L., additional, Calvaruso, V., additional, Colecchia, A., additional, Di Maria, G., additional, La Mantia, C., additional, Lin, H., additional, Mendoza, Y., additional, Pugliese, N., additional, Ravaioli, F., additional, Lara-Romero, C., additional, Saltini, D., additional, Craxì, A., additional, Di Marco, V., additional, Cammà, C., additional, and Petta, S., additional

Published
2023
Full Text
View/download PDF

29. T.11.6 TREATMENT WITH GLECAPREVIR AND PIBRENTASVIR IS SAFE AND EFFECTIVE IN ITALIAN

Author

Mastrorocco, E., primary, De Marco, A., additional, Pugliese, N., additional, Calvaruso, V., additional, Masarone, M., additional, D'Ambrosio, R., additional, Battistella, S., additional, Licata, A., additional, Persico, M., additional, Anolli, M.P., additional, Russo, F., additional, Distefano, M., additional, Petta, S., additional, Di Marco, V., additional, and Aghemo, A., additional

Published
2023
Full Text
View/download PDF

30. Prevalence and predictiors of porto-sinusoidal vascular disorder in patients with constantly elevated gamma-glutamyl transferase levels: A multicenter Italian study

Author

Pugliese, N., primary, Viganò, M., additional, Di Tommaso, L., additional, Maggioni, M., additional, Cerini, F., additional, Santopaolo, F., additional, Bianco, C., additional, Masetti, C., additional, Lleo, A., additional, Manini, M.A., additional, Valenti, L., additional, Giustiniani, M.C., additional, Ponziani, F.R., additional, Terracciano, L., additional, and Aghemo, A., additional

Published
2023
Full Text
View/download PDF

31. OC.12.5 MYOSTEATOSIS IS NOT ASSOCIATED WITH COMPLICATIONS OR SURVIVAL IN HCC PATIENTS UNDERGOING TRANS ARTERIAL EMBOLIZATION

Author

De Marco, A., primary, Masetti, C., additional, Pugliese, N., additional, Lofino, L., additional, Colapietro, F., additional, Ceriani, R., additional, Lleo, A., additional, Poretti, D., additional, Pedicini, V., additional, De Nicola, S., additional, Torzilli, G., additional, Rimassa, L., additional, Aghemo, A., additional, and Lanza, E., additional

Published
2023
Full Text
View/download PDF

33. Haemodynamic forces as predictors of cardiac remodelling and outcome in heart failure with reduced ejection fraction treated with sacubitril/valsartan

Author

Fabiani, I, primary, Pugliese, N R, additional, Castiglione, V, additional, Pedrizzetti, G, additional, Tonti, G, additional, Chubuchny, V, additional, Becherini, F, additional, Taddei, C, additional, Gimelli, A, additional, Del Punta, L, additional, Balletti, A, additional, Masi, S, additional, Cameli, M, additional, Emdin, M, additional, and Giannoni, A, additional

Published
2022
Full Text
View/download PDF

34. The impact of ventricular-arterial coupling on aerobic capacity across the heart failure spectrum

Author

Pugliese, N R, primary, Balletti, A, additional, Armenia, S, additional, De Biase, N, additional, Faita, F, additional, Mengozzi, A, additional, Paneni, F, additional, Ruschitzka, F, additional, Virdis, A, additional, Ghiadoni, L, additional, Taddei, S, additional, Williams, B, additional, Antonini-Canterin, F, additional, and Masi, S, additional

Published
2022
Full Text
View/download PDF

35. The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk

Author

Pugliese, N, Mengozzi, A, Virdis, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Parati, G, Palatini, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Masi, S, Borghi, C, Pugliese N. R., Mengozzi A., Virdis A., Casiglia E., Tikhonoff V., Cicero A. F. G., Ungar A., Rivasi G., Salvetti M., Barbagallo C. M., Bombelli M., Dell'Oro R., Bruno B., Lippa L., D'Elia L., Verdecchia P., Mallamaci F., Cirillo M., Rattazzi M., Cirillo P., Gesualdo L., Mazza A., Giannattasio C., Maloberti A., Volpe M., Tocci G., Georgiopoulos G., Iaccarino G., Nazzaro P., Parati G., Palatini P., Galletti F., Ferri C., Desideri G., Viazzi F., Pontremoli R., Muiesan M. L., Grassi G., Masi S., Borghi C., Pugliese, N, Mengozzi, A, Virdis, A, Casiglia, E, Tikhonoff, V, Cicero, A, Ungar, A, Rivasi, G, Salvetti, M, Barbagallo, C, Bombelli, M, Dell'Oro, R, Bruno, B, Lippa, L, D'Elia, L, Verdecchia, P, Mallamaci, F, Cirillo, M, Rattazzi, M, Cirillo, P, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Volpe, M, Tocci, G, Georgiopoulos, G, Iaccarino, G, Nazzaro, P, Parati, G, Palatini, P, Galletti, F, Ferri, C, Desideri, G, Viazzi, F, Pontremoli, R, Muiesan, M, Grassi, G, Masi, S, Borghi, C, Pugliese N. R., Mengozzi A., Virdis A., Casiglia E., Tikhonoff V., Cicero A. F. G., Ungar A., Rivasi G., Salvetti M., Barbagallo C. M., Bombelli M., Dell'Oro R., Bruno B., Lippa L., D'Elia L., Verdecchia P., Mallamaci F., Cirillo M., Rattazzi M., Cirillo P., Gesualdo L., Mazza A., Giannattasio C., Maloberti A., Volpe M., Tocci G., Georgiopoulos G., Iaccarino G., Nazzaro P., Parati G., Palatini P., Galletti F., Ferri C., Desideri G., Viazzi F., Pontremoli R., Muiesan M. L., Grassi G., Masi S., and Borghi C.

Abstract

Introduction: Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis. Aim: We assessed the prognostic role of SUA in patients with and without MS. Methods: We used data from the multicentre Uric Acid Right for Heart Health study and considered cardiovascular mortality (CVM) as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. Results: A total of 9589 subjects (median age 58.5 years, 45% males) were included in the analysis, and 5100 (53%) patients had a final diagnosis of MS. After a median follow-up of 142 months, we observed 558 events. Using a previously validated cardiovascular SUA cut-off to predict CVM (> 5.1 mg/dL in women and 5.6 mg/dL in men), elevated SUA levels were significantly associated to a worse outcome in patients with and without MS (all p < 0.0001) and provided a significant net reclassification improvement of 7.1% over the diagnosis of MS for CVM (p = 0.004). Cox regression analyses identified an independent association between SUA and CVM (Hazard Ratio: 1.79 [95% CI, 1.15–2.79]; p < 0.0001) after the adjustment for MS, its single components and renal function. Three specific combinations of the MS components were associated with higher CVM when increasing SUA levels were reported, and systemic hypertension was the only individual component ever-present (all p < 0.0001). Conclusion: Increasing SUA levels are associated with a higher CVM risk irrespective of the presence of MS: a cardiovascular SUA threshold may improve risk stratification. Graphic abstract: [Figure not available: see fulltext.]

Published
2021

36. Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19”

Author

Iavarone, M, D'Ambrosio, R, Lampertico, P, Rimondi, A, Soria, A, Bonfanti, P, Triolo, M, Fagiuoli, S, Pugliese, N, Aghemo, A, Del Poggio, P, Perricone, G, Belli, L, Massironi, S, Luca, M, Invernizzi, P, Spinetti, A, Carriero, C, Buscarini, E, Pedaci, M, Vigano, M, Rumi, M, Iavarone M., D'Ambrosio R., Lampertico P., Rimondi A., Soria A., Bonfanti P., Triolo M., Fagiuoli S., Pugliese N., Aghemo A., Del Poggio P., Perricone G., Belli L. S., Massironi S., Luca M., Invernizzi P., Spinetti A., Carriero C., Buscarini E., Pedaci M., Vigano M., Rumi M. G., Iavarone, M, D'Ambrosio, R, Lampertico, P, Rimondi, A, Soria, A, Bonfanti, P, Triolo, M, Fagiuoli, S, Pugliese, N, Aghemo, A, Del Poggio, P, Perricone, G, Belli, L, Massironi, S, Luca, M, Invernizzi, P, Spinetti, A, Carriero, C, Buscarini, E, Pedaci, M, Vigano, M, Rumi, M, Iavarone M., D'Ambrosio R., Lampertico P., Rimondi A., Soria A., Bonfanti P., Triolo M., Fagiuoli S., Pugliese N., Aghemo A., Del Poggio P., Perricone G., Belli L. S., Massironi S., Luca M., Invernizzi P., Spinetti A., Carriero C., Buscarini E., Pedaci M., Vigano M., and Rumi M. G.

Published
2020

37. The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome

Author

Mengozzi, A., Georgiopoulos, G., Falcone, M., Tiseo, G., Pugliese, N. R., Dimopoulos, M. A., Ghiadoni, L., Barbieri, G., Forfori, F., Carrozzi, L., Santini, M., Monzani, F., De Marco, S., Menichetti, F., Virdis, A., Masi, S., Sabrina, A. D. I., Martina, B., Matteo, B., Elia, N., Stefano, S., Rachele, A., Valeria, C., Simone, P., Rubia, B., Pietro, B., Giulia, B., Forfori, Francesco, Alessandra, D. R., Fabio, G., Paolo, M., Marco, M., Chiara, P., Alessandro, C., Francesco, C., Naria, P., Luciano, C., Chiara, S., Valentina, G., Uliana, M., Francesca, R., Giovanna, F., and Maria, S.

Subjects
Male, Hemodynamics, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Prognostic markers, 0302 clinical medicine, Clinical endpoint, Hospital Mortality, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, education.field_of_study, Multidisciplinary, Confounding, Low-Molecular-Weight, Blood Coagulation Disorders, Middle Aged, Prognosis, C-Reactive Protein, Cardiology, Medicine, Female, Risk, medicine.medical_specialty, Heart Diseases, medicine.drug_class, Science, Population, Low molecular weight heparin, Predictive markers, COVID-19, Fibrin Fibrinogen Degradation Products, Heparin, Low-Molecular-Weight, Humans, Inflammation, SARS-CoV-2, Troponin T, Article, 03 medical and health sciences, Internal medicine, medicine, Coagulopathy, education, Heparin, business.industry, medicine.disease, Observational study, business
Abstract

Introduction: High sensitivity troponin T (hsTnT) is a strong predictor of adverse outcome during SARS-CoV-2 infection. However, its determinants remain partially unknown. We aimed to assess the relationship between severity of inflammatory response/coagulation abnormalities and hsTnT in Coronavirus Disease 2019 (COVID-19). We then explored the relevance of these pathways in defining mortality and complications risk and the potential effects of the treatments to attenuate such risk.Methods: In this single-center, prospective, observational study we enrolled 266 consecutive patients hospitalized for SARS-CoV-2 pneumonia. Primary endpoint was in-hospital COVID-19 mortality. Results: hsTnT, even after adjustment for confounders, was associated with mortality. D-dimer and CRP presented stronger associations with hsTnT than PaO2. Changes of hsTnT, D-dimer and CRP were related but only D-dimer was associated with mortality. Moreover, low molecular weight heparin showed attenuation of the mortality in the whole population, particularly in subjects with higher hsTnT.Conclusions: D-dimer possessed a strong relationship with hsTnT and mortality. Anticoagulation treatment showed greater benefits with regard to mortality. These findings suggest a major role of SARS-CoV-2 coagulopathy in hsTnT elevation and its related mortality in COVID-19. A better understanding of the mechanisms related to COVID-19 might pave the way to therapy tailoring in these high-risk individuals.

Published
2021

38. Development and validation of a decision support tool for the diagnosis of acute heart failure: Systematic review, meta-analysis, and modelling study

Author

Lee, K, Doudesis, D, Anwar, M, Astengo, F, Chenevier-Gobeaux, C, Claessens, Y, Wussler, D, Kozhuharov, N, Strebel, I, Sabti, Z, Defilippi, C, Seliger, S, Moe, G, Fernando, C, Bayes-Genis, A, van Kimmenade, R, Pinto, Y, Gaggin, H, Wiemer, J, Möckel, M, Rutten, J, van den Meiracker, A, Gargani, L, Pugliese, N, Pemberton, C, Ibrahim, I, Gegenhuber, A, Mueller, T, Neumaier, M, Behnes, M, Akin, I, Bombelli, M, Grassi, G, Nazerian, P, Albano, G, Bahrmann, P, Newby, D, Japp, A, Tsanas, A, Shah, A, Richards, A, Mcmurray, J, Mueller, C, Januzzi, J, Mills, N, Lee, Kuan Ken, Doudesis, Dimitrios, Anwar, Mohamed, Astengo, Federica, Chenevier-Gobeaux, Camille, Claessens, Yann-Erick, Wussler, Desiree, Kozhuharov, Nikola, Strebel, Ivo, Sabti, Zaid, deFilippi, Christopher, Seliger, Stephen, Moe, Gordon, Fernando, Carlos, Bayes-Genis, Antoni, van Kimmenade, Roland R J, Pinto, Yigal, Gaggin, Hanna K, Wiemer, Jan C, Möckel, Martin, Rutten, Joost H W, van den Meiracker, Anton H, Gargani, Luna, Pugliese, Nicola R, Pemberton, Christopher, Ibrahim, Irwani, Gegenhuber, Alfons, Mueller, Thomas, Neumaier, Michael, Behnes, Michael, Akin, Ibrahim, Bombelli, Michele, Grassi, Guido, Nazerian, Peiman, Albano, Giovanni, Bahrmann, Philipp, Newby, David E, Japp, Alan G, Tsanas, Athanasios, Shah, Anoop S V, Richards, A Mark, McMurray, John J V, Mueller, Christian, Januzzi, James L, Mills, Nicholas L, Lee, K, Doudesis, D, Anwar, M, Astengo, F, Chenevier-Gobeaux, C, Claessens, Y, Wussler, D, Kozhuharov, N, Strebel, I, Sabti, Z, Defilippi, C, Seliger, S, Moe, G, Fernando, C, Bayes-Genis, A, van Kimmenade, R, Pinto, Y, Gaggin, H, Wiemer, J, Möckel, M, Rutten, J, van den Meiracker, A, Gargani, L, Pugliese, N, Pemberton, C, Ibrahim, I, Gegenhuber, A, Mueller, T, Neumaier, M, Behnes, M, Akin, I, Bombelli, M, Grassi, G, Nazerian, P, Albano, G, Bahrmann, P, Newby, D, Japp, A, Tsanas, A, Shah, A, Richards, A, Mcmurray, J, Mueller, C, Januzzi, J, Mills, N, Lee, Kuan Ken, Doudesis, Dimitrios, Anwar, Mohamed, Astengo, Federica, Chenevier-Gobeaux, Camille, Claessens, Yann-Erick, Wussler, Desiree, Kozhuharov, Nikola, Strebel, Ivo, Sabti, Zaid, deFilippi, Christopher, Seliger, Stephen, Moe, Gordon, Fernando, Carlos, Bayes-Genis, Antoni, van Kimmenade, Roland R J, Pinto, Yigal, Gaggin, Hanna K, Wiemer, Jan C, Möckel, Martin, Rutten, Joost H W, van den Meiracker, Anton H, Gargani, Luna, Pugliese, Nicola R, Pemberton, Christopher, Ibrahim, Irwani, Gegenhuber, Alfons, Mueller, Thomas, Neumaier, Michael, Behnes, Michael, Akin, Ibrahim, Bombelli, Michele, Grassi, Guido, Nazerian, Peiman, Albano, Giovanni, Bahrmann, Philipp, Newby, David E, Japp, Alan G, Tsanas, Athanasios, Shah, Anoop S V, Richards, A Mark, McMurray, John J V, Mueller, Christian, Januzzi, James L, and Mills, Nicholas L

Abstract

Objectives: To evaluate the diagnostic performance of N-terminal pro-B-type natriuretic peptide (NT-proBNP) thresholds for acute heart failure and to develop and validate a decision support tool that combines NT-proBNP concentrations with clinical characteristics. Design: Individual patient level data meta-analysis and modelling study. Setting: Fourteen studies from 13 countries, including randomised controlled trials and prospective observational studies. Participants: Individual patient level data for 10 369 patients with suspected acute heart failure were pooled for the meta-analysis to evaluate NT-proBNP thresholds. A decision support tool (Collaboration for the Diagnosis and Evaluation of Heart Failure (CoDE-HF)) that combines NT-proBNP with clinical variables to report the probability of acute heart failure for an individual patient was developed and validated. Main outcome measure: Adjudicated diagnosis of acute heart failure. Results: Overall, 43.9% (4549/10 369) of patients had an adjudicated diagnosis of acute heart failure (73.3% (2286/3119) and 29.0% (1802/6208) in those with and without previous heart failure, respectively). The negative predictive value of the guideline recommended rule-out threshold of 300 pg/mL was 94.6% (95% confidence interval 91.9% to 96.4%); despite use of age specific rule-in thresholds, the positive predictive value varied at 61.0% (55.3% to 66.4%), 73.5% (62.3% to 82.3%), and 80.2% (70.9% to 87.1%), in patients aged [removed]75 years, respectively. Performance varied in most subgroups, particularly patients with obesity, renal impairment, or previous heart failure. CoDE-HF was well calibrated, with excellent discrimination in patients with and without previous heart failure (area under the receiver operator curve 0.846 (0.830 to 0.862) and 0.925 (0.919 to 0.932) and Brier scores of 0.130 and 0.099, respectively). In patients without previous heart failure, the diagnostic performance was consistent across all subgroups

Published
2022

39. Screening for Fabry disease in patients with ischaemic stroke at young age: the Italian Project on Stroke in Young Adults

Author

Poli, L., Zedde, M., Zini, A., Del Sette, M., Lodigiani, C., Spalloni, A., Di Lisi, F., Toriello, A., Piras, V., Stilo, C., Tomelleri, G., Tancredi, L., Paciaroni, M., Silvestrelli, G., Adami, A., Costa, P., Morotti, A., De Giuli, V., Caria, F., Gamba, M., Malferrari, G., Simone, A. M., Musolino, R., Giorli, E., Banfi, E., Marcheselli, S., Rasura, M., Pugliese, N., Melis, M., Bovi, P., Padovani, A., Burlina, A., Pezzini, A., Del Zotto, Elisabetta, Giossi, Alessia, Sessa, Maria, Gilberti, Nicola, Magoni, Mauro, Ferrazzi, Paola, Librè, Luca, Rota, Lidia Luciana, Patella, Rosalba, Di Liso, Filomena, Calabrò, Rocco Salvatore, Bramanti, Placido, La Spina, Paolo, Finocchi, Cinzia, Balestrino, Maurizio, Bruno, Chiara, Massucco, Davide, Gandolfo, Carlo, Traverso, Elisabetta, DeLodovici, Maria Luisa, Verrengia, Elena Pinuccia, Carimati, Federico, Bono, Giorgio, DellʼAcqua, Maria Luisa, Bigliardi, Guido, Vandelli, Laura, Nichelli, Paolo Frigio, Carletti, Monica, Cerrato, Paolo, Iacoviello, Licia, Di Castelnuovo, Augusto, de Gaetano, Giovanni, Grassi, Mario, Locatelli, Giampiero, Caso, Valeria, DʼAmore, Cataldo, Agnelli, Giancarlo, Checcarelli, Nicoletta, Guidotti, Mario, Arnaboldi, Marco, Giacalone, Giacomo, Zanoli, Elisa, Cavallini, Anna, Persico, Alessandra, Micieli, Giuseppe, Chiti, Alberto, Orlandi, Giovanni, Marchi, Piernicola, Lanari, Alessia, Ciccone, Alfonso, Cucurachi, Laura, Bonifati, Marco Domenico, and Marcello, Norina

Published
2017
Full Text
View/download PDF

41. P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME

Author

Palandri, F., primary, Bartoletti, D., additional, Breccia, M., additional, Auteri, G., additional, Elli, E. M., additional, Trawinska, M. M., additional, Polverelli, N., additional, Tiribelli, M., additional, Benevolo, G., additional, Iurlo, A., additional, Tieghi, A., additional, Heidel, F. H., additional, Caocci, G., additional, Beggiato, E., additional, Binotto, G., additional, Cavazzini, F., additional, Miglino, M., additional, Bosi, C., additional, Crugnola, M., additional, Bocchia, M., additional, Martino, B., additional, Pugliese, N., additional, Romagnoli, A. D., additional, Mazzoni, C., additional, Scaffidi, L., additional, Isidori, A., additional, Cattaneo, D., additional, Krampera, M., additional, Pane, F., additional, Cilloni, D., additional, Semenzato, G., additional, Lemoli, R. M., additional, Cuneo, A., additional, Abruzzese, E., additional, Vianelli, N., additional, Cavo, M., additional, Bonifacio, M., additional, and Palumbo, G. A., additional

Published
2022
Full Text
View/download PDF

43. T.03.2 MULTICENTER STUDY OF COLD VERSUS HOT EMR FOR LARGE DUODENAL ADENOMAS

Author

Capogreco, A., primary, Spadaccini, M., additional, Maselli, R., additional, Galtieri, P.A., additional, Pellegatta, G., additional, Fugazza, A., additional, Anderloni, A., additional, Ferrara, E.C., additional, Carrara, S., additional, Vespa, E., additional, Pugliese, N., additional, Parigi, T., additional, Schachschal, G., additional, Creutzfeldt, A., additional, Hassan, C., additional, Bhandari, P., additional, Meining, A., additional, Rösch, T., additional, and Repici, A., additional

Published
2022
Full Text
View/download PDF

44. MULTICENTER STUDY OF COLD VERSUS HOT EMR FOR LARGE DUODENAL ADENOMAS

Author

Capogreco, A., additional, Spadaccini, M., additional, Maselli, R., additional, Hassan, C., additional, Galtieri, P.A., additional, Pellegatta, G., additional, Anderloni, A., additional, Fugazza, A., additional, Carrara, S., additional, Ferrara, E.C., additional, Colombo, M., additional, Vespa, E., additional, Pugliese, N., additional, Parigi, T., additional, Schachschal, G., additional, Creutzfeldt, A., additional, Bhandari, P., additional, Meining, A., additional, Rosch, T., additional, and Repici, A., additional

Published
2022
Full Text
View/download PDF

48. Feasibility of semi-recumbent bicycle exercise Doppler echocardiography for the evaluation of the right heart and pulmonary circulation unit in different clinical conditions: the RIGHT heart international NETwork (RIGHT-NET)

Author

Ferrara F., Gargani L., Naeije R., Rudski L., Armstrong W. F., Wierzbowska-Drabik K., Argiento P., Bandera F., Cademartiri F., Citro R., Cittadini A., Cocchia R., Contaldi C., D'Alto M., D'Andrea A., Grunig E., Guazzi M., Kolias T. J., Limongelli G., Marra A. M., Mauro C., Moreo A., Ranieri B., Saggar R., Salzano A., Stanziola A. A., Vriz O., Vannan M., Kasprzak J. D., Bossone E., Capuano F., Benvenga R., Bellino M., Radano I., Marra A., D'Assante R., Rega S., Mazzola M., Raciti M., Dellegrottaglie S., De Luca N., Rozza F., Russo V., Di Salvo G., Ghio S., Guida S., Eichstaedt C. A., Labate V., La Gerche A., Pacileo G., Verrengia M., Kovacs G., Douschan P., Casadei F., De Chiara B., Ostenfeld E., Pedrizzetti G., Pieri F., Mori F., Moggi-Pignone A., Pratali L., Pugliese N., Selton-Suty C., Huttin O., Venner C., Serra W., Tafuni F., Stanziola A., Martino M., Caccavo G., Szabo I., Varga A., Agoston G., Voilliot D., Mobasseri S., Flueckiger P., Liu S., Ferrara, F., Gargani, L., Naeije, R., Rudski, L., Armstrong, W. F., Wierzbowska-Drabik, K., Argiento, P., Bandera, F., Cademartiri, F., Citro, R., Cittadini, A., Cocchia, R., Contaldi, C., D'Alto, M., D'Andrea, A., Grunig, E., Guazzi, M., Kolias, T. J., Limongelli, G., Marra, A. M., Mauro, C., Moreo, A., Ranieri, B., Saggar, R., Salzano, A., Stanziola, A. A., Vriz, O., Vannan, M., Kasprzak, J. D., Bossone, E., Capuano, F., Benvenga, R., Bellino, M., Radano, I., Marra, A., D'Assante, R., Rega, S., Mazzola, M., Raciti, M., Dellegrottaglie, S., De Luca, N., Rozza, F., Russo, V., Di Salvo, G., Ghio, S., Guida, S., Eichstaedt, C. A., Labate, V., La Gerche, A., Pacileo, G., Verrengia, M., Kovacs, G., Douschan, P., Casadei, F., De Chiara, B., Ostenfeld, E., Pedrizzetti, G., Pieri, F., Mori, F., Moggi-Pignone, A., Pratali, L., Pugliese, N., Selton-Suty, C., Huttin, O., Venner, C., Serra, W., Tafuni, F., Stanziola, A., Martino, M., Caccavo, G., Szabo, I., Varga, A., Agoston, G., Voilliot, D., Mobasseri, S., Flueckiger, P., and Liu, S.

Subjects
Adult, medicine.medical_specialty, Pulmonary Circulation, Adolescent, Ventricular Dysfunction, Right, Atrial Pressure, Population, Right heart, Predictive Value of Test, Regurgitation (circulation), 030204 cardiovascular system & hematology, Doppler echocardiography, Pulmonary hypertension, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Predictive Value of Tests, Internal medicine, medicine.artery, medicine, Ventricular outflow tract, Humans, Radiology, Nuclear Medicine and imaging, education, Cardiac imaging, Exercise Doppler echocardiography, Aged, Aged, 80 and over, education.field_of_study, medicine.diagnostic_test, business.industry, Middle Aged, medicine.disease, Echocardiography, Doppler, Bicycling, Feasibility Studie, 030228 respiratory system, Pulmonary artery, Cardiology, cardiovascular system, Ventricular Function, Right, Right ventricle, Feasibility Studies, Female, Cardiology and Cardiovascular Medicine, business, Human
Abstract

Exercise Doppler echocardiography (EDE) is a well-validated tool in ischemic and valvular heart diseases. However, its use in the assessment of the right heart and pulmonary circulation unit (RH-PCU) is limited. The aim of this study is to assess the semi-recumbent bicycle EDE feasibility for the evaluation of RH-PCU in a large multi-center population, from healthy individuals and elite athletes to patients with overt or at risk of developing pulmonary hypertension (PH). From January 2019 to July 2019, 954 subjects [mean age 54.2 ± 16.4years, range 16–96, 430 women] underwent standardized semi-recumbent bicycle EDE with an incremental workload of 25 watts every 2min, were prospectively enrolled among 7 centers participating to the RIGHT Heart International NETwork (RIGHT-NET). EDE parameters of right heart structure, function and pressures were obtained according to current recommendations. Right ventricular (RV) function at peak exercise was feasible in 903/940 (96%) by tricuspid annular plane systolic excursion (TAPSE), 667/751 (89%) by tissue Doppler-derived tricuspid lateral annular systolic velocity (S′) and 445/672 (66.2%) by right ventricular fractional area change (RVFAC). RV—right atrial pressure gradient [RV–RA gradient = 4 × tricuspid regurgitation velocity2 (TRV)] was feasible in 894/954 patients (93.7%) at rest and in 816/954 (85.5%) at peak exercise. The feasibility rate in estimating pulmonary artery pressure improved to more than 95%, if both TRV and/or right ventricular outflow tract acceleration time (RVOT AcT) were considered. In high specialized echocardiography laboratories semi-recumbent bicycle EDE is a feasible tool for the assessment of the RH-PCU pressure and function.

Published
2021

49. High rates of histological findings compatible with porto-sinusoidal vascular liver disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy

Author

Pugliese, N., primary, Di Tommaso, L., additional, Ceriani, R., additional, Alfarone, L., additional, Mastrorocco, E., additional, Terrin, M., additional, Solitano, V., additional, Masetti, C., additional, Colapietro, F., additional, Lleo, A., additional, Terracciano, L., additional, and Aghemo, A., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results